Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B

New England Journal of Medicine

Volumn 369, Issue 24, 2013, Pages 2313-2323

  Powell, Jerry S ^a   Pasi, K John ^b   Ragni, Margaret V ^c   Ozelo, Margareth C ^d   Valentino, Leonard A ^e   Mahlangu, Johnny N ^f   Josephson, Neil C ^h   Perry, David ⁱ   Manco Johnson, Marilyn J ^j   Apte, Shashikant ^k   Baker, Ross I ^l   Chan, Godfrey C ^m   Novitzky, Nicolas ^g   Wong, Raymond S ⁿ   Krassova, Snejana ^o   Allen, Geoffrey ^o   Jiang, Haiyan ^o   Innes, Alison ^o   Li, Shuanglian ^o   Cristiano, Lynda M ^o   Goyal, Jaya ^o   Sommer, Jurg M ^o   Dumont, Jennifer A ^o   Nugent, Karen ^o   Vigliani, Gloria ^p   Brennan, Aoife ^o   Luk, Alvin ^o   Pierce, Glenn F ^o   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF CAMPINAS   (Brazil)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h PUGET SOUND BLOOD CENTER   (United States)

ⁱ ADDENBROOKE S HOSPITAL   (United Kingdom)

^j UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^k Sahyadri Hospital   (India)

^l MURDOCH UNIVERSITY   (Australia)

^m UNIVERSITY OF HONG KONG   (Hong Kong)

ⁿ CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^o BIOGEN   (United States)

^p NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 9; FC RECOMBINANT FACTOR IX FUSION PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTICLE; BLEEDING; BLOOD LEVEL; CHILD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HEMOPHILIA B; HUMAN; HYPERTENSION; INCIDENCE; INFLUENZA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; THROMBOSIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 84889769562     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1305074     Document Type: Article

References (40)

1. Giangrande P. Haemophilia B: Christmas disease. Expert Opin Pharmacother 2005;6:1517-24.
2. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001;344:1773-9. [Erratum, N Engl J Med 2001;345:384.]
3. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32.
4. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44.
5. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 1994;236:391-9.
6. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003;9:272-8.
7. Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976;65:129-35.
8. White GC II, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997;78:261-5.
9. National Hemophilia Foundation. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Medical and Scientific Advisory Council document #179 (http://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/ masac179.pdf).
10. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Hemophilia 2001;7:392-6.
11. Mannucci PM, Mancuso ME. Investigational drugs for coagulation disorders. Expert Opin Investig Drugs 2013;22:945-53.
12. Pipe SW. Hemophilia: new protein therapeutics. Hematology Am Soc Hematol Educ Program 2010;2010:203-9.
13. Martinowitz U, Shapiro A, Quon DV, et al. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. Haemophilia 2012;18:881-7.
14. Negrier C, Knobe K, Tiede A, Giangrande P, Møss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011;118:2695-701.
15. Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010;115:2057-64.
16. Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012;120:2405-11.
17. Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood2012;119:666-72.
18. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-7.
19. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365:2357-65.
20. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7:715-25.
21. Rath T, Baker K, Dumont JA, et al. Fc-fusion proteins and FcRn: structural insights for longer lasting and more effective therapeutics. Crit Rev Biotechnol 2013 October 24 (Epub ahead of print).
22. Committee for Medicinal Products for Human Use (CHMP). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. London: European Medicines Agency, 2007 (http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003946.pdf).
23. Guidance for industry: draft guidance - assay development for immunogenicity testing of therapeutic proteins. Silver Spring, MD: Food and Drug Administration, 2009 (http://www.fda.gov/downloads/Drugs/.../Guidances/ UCM192750.pdf).
24. Clopper C, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:404-13.
25. BeneFIX (coagulation factor IX [Recombinant]). Pfizer, 2011 (package insert) (http://labeling.pfizer.com/showlabeling.aspx?id=492).
26. Kisker CT, Eisberg A, Schwartz B. Prophylaxis in factor IX deficiency product and patient variation. Haemophilia 2003;9:279-84.
27. Lambert T, Recht M, Valentino LA, et al. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 2007;13:233-43. [Erratum, Haemophilia 2007;13:450.]
28. Ewenstein BM, Joist JH, Shapiro AD, et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002;42:190-7.
29. Ragni MV, Pasi KJ, White GC, Giangrande PL, Courter SG, Tubridy KL. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 2002;8:91-7.
30. Chang HH, Yang YL, Hung MH, Tsay W, Shen MC. Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan. J Formos Med Assoc 2007;106:281-7.
31. Lissitchkov T, Matysiak M, Zavilska K, et al. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine) and a recombinant factor IX (BeneFIX) in patients with severe haemophilia B. Haemophilia 2013;19:674-8.
32. Dimichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002;8:280-7.
33. Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009;15:1027-31.
34. Recht M, Pollmann H, Tagliaferri A, Musso R, Janco R, Neuman WR. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia 2011;17:494-9.
35. Tandra A, Shapiro AD. Treatment of inhibitors in hemophilia B. In: Lee CA, Berntorp E, Hoots WK, eds. Textbook of hemophilia. 2nd ed. Hoboken, NJ: Wiley-Blackwell, 2010:97-103.
36. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007;138:305-15.
37. Klintman J, Hillarp A, Donfield S, Berntorp E, Astermark J. Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A. Haemophilia 2013;19:106-12.
38. Whelan SF, Hofbauer CJ, Horling FM, et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013;121:1039-48.
39. Guideline on clinical investigation of recombinant and human plasma-derived factor IX products. London: European Medicines Agency, 2012 (http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/ 08/WC500109691.pdf).
40. Dimichele DM, Blanchette V, Berntorp E. Clinical trial design in haemophilia. Haemophilia 2012;18: Suppl 4:18-23.